Latest:
Updates on Multiple Myeloma Diagnosis and Treatment Strategies
Progress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Sonja Althammer, PhD
Latest:
Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC
Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.
Sophie D. Fosså, MD, PhD
Latest:
Dr. Fosså on Radiotherapy/ Antiandrogen Therapy
Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.
Sophie Papa, PhD, MBBS, MRCP
Latest:
Dr. Papa on Leukapheresis Manufacturing Approach in Head and Neck Cancer
Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses leukapheresis manufacturing approach in head and neck cancer.
Sponsored Content
Latest:
ESMO Data Show More Can Be Done for Cancer of Unknown Primary Patients
Two research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology (ESMO) Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial, according to ESMO guidelines.
Sponsored Content by Amgen
Latest:
Biosimilars in Cancer Care: Potentially Improving Patient Access to Essential Therapies9,10
Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.
Sponsored Content by Iovance Biotherapeutics, Inc
Latest:
TIL Therapy May Provide Second-Line Option for Cervical Cancer
Investigators are optimistic that LN-145, an autologous tumor-infiltrating lymphocyte investigational therapy, could be a potential treatment option for patients with recurrent, metastatic, or persistent cervical cancer.
Sponsored Content by Janssen Pharmaceutical Companies of Johnson & Johnson
Latest:
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Offers Subcutaneous CD38-Directed Antibody to Health Care Providers and Their Multiple Myeloma Patients
Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.
Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center
Latest:
Role of JAK-STAT Pathway in Myelofibrosis
Aaron Gerds, MD, MS; and Srdan Verstovsek, MD, PhD, share insights on the impact of pathways, including JAK-STAT, on myelofibrosis disease progression and discuss considerations for the use of JAK inhibitors.